Does acute lymphoblastic leukemia or its treatment help controlling asthma : a Belgian retrospective review. by Geurten, Claire et al.
•There was a significant positive influence of ALL 
treatment in children suffering from a respiratory 
condition before therapy. 
•This might be - at least in part - due to the effects of 
corticotherapy/immunosuppressive effects of therapy. 
•Prospective studies are needed to confirm our 
hypotheses and further assess the relationships 
between respiratory conditions and ALL/NBL.
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•Association of chronic inflammatory respiratory 
conditions such as asthma and viral induced-wheeze 
with acute malignancies have rarely been studied in 
children.   Little is known about how chemotherapy may 
affect respiratory symptoms and respiratory function in 
children affected with both conditions.  
•An overall decreased risk for malignancies in 
children affected with asthma has been evoked. 
•Another hypothesis suggests an enhanced control of 
asthma in children on and off cancer therapy through 
immunosuppressive effect of chemotherapy or hygiene 
measures imposed on patients on chemotherapy, 
reducing exposure to viral infections and other potential 
triggers 
•As survival of childhood malignancies increases, 
practitioners are increasingly solicited by a new 
population of childhood cancer survivors whose chronic 
conditions require adequate management. 
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•Medical files of patients diagnosed with acute 
lymphoblastic leukemia (ALL) in a tertiary centre in 
Belgium between 1987 and 2016 were reviewed to assess 
the prevalence of asthma or viral-induced wheeze in this 
population and to study their evolution and the need for 
B2 agonists and inhaled corticosteroid (ICS) before and 
after treatment of leukemia.  
•Data were compared to those obtained in patients 
treated for neuroblastoma (NBL)
•Prevalence of asthma and viral-induced wheeze is 
lower in patients diagnosed with malignancies and in 
survivors than in general population 
•Relative risk (RR) of having a respiratory 
condition after treatment is significantly lower in 
patients with ALL than with NBL, probably due to 
the benefit of high-dose corticotherapy administered 
during induction of ALL therapy and due to the 
immunosuppressive effects of chemotherapy. 
•Onset of new respiratory conditions is noted, but is 
similar to the prevalence of onset in the general 
population (natural evolution?) 
ALL 
•ALL treatment influenced significantly the 
evolution of viral induced wheeze (all previous 
wheezers were weaned off reliever therapy) and 
upper respiratory infections, but not asthma 
•Use of B2 agonist is significantly lower after ALL 
therapy 
•These effects may be due to the use of 
immunosuppressive drugs/corticosteroid or merely 
be due to the natural evolution of the disease 
•Viral-induced exacerbations were reported in 4% 
of patients during therapy  
         We believe that even if hygiene measures are 
applied, the immunosuppressive effects of therapy 
maintain the patients at risk for respiratory 
infections 
NBL  
•There were no significant effect of cancer therapy 
on respiratory condition or use of reliever therapy
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•General population (Belgium) : 6-8,5% of 










After end of 
therapy
Sex 
- M/F 65 (62,5%)/ 39 (37,5%) 22 (43%) / 29 (57%)





























Patients cured 10 % 4 %








2 (2%)    
RR = 0,33, p = 0.04 
10 (10%)  
RR = 5, NS
1 (2%) 
0 (0%)
0 (0%)  
RR = 3, NS 
2 (4%)  
RR = 3, NS
Atopy 7 (7 %) 5 (10 %)
RESULTS
